FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Supplemental Application (Par Health USA, LLC)

View source ↗

Summary

FDA approves a supplemental abbreviated new drug application for Lamotrigine Extended Release from Par Health USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Seizure Disorder

Drugs mentioned

• Lamotrigine Extended-Release (Lamotrigine extended-release)

Snippet

SUPPL AP for LAMOTRIGINE EXTENDED RELEASE (LAMOTRIGINE EXTENDED RELEASE)